Degenerative Lumbar Spinal Stenosis
Conditions
Brief summary
This is a long-term follow-up study for more than 3 years to evaluate the efficacy and safety of bioactive glass-ceramic intervertebral spacer (Novomax) in posterior lumbar interbody fusion.
Detailed description
During one-level PLIF, bioactive glass-ceramic intervertebral spacer (Novomax) and titanium cage were inserted in the experimental group and control group, respectively. Bone fusion by simple radiography had angular deformity of less than 3 degrees and a potential of less than 3 mm in flexion extension radiographs, and thin-section CT (\<2 mm) was used to determine the combination between the vertebral endplate and the autogenous bone or bioactive glass-ceramic intervertebral spacer (Novomax) in the cage without any gaps or the part connected to bony trabecula as fusion, and both groups will be compared.
Interventions
DEVICEBioactive Glass-Ceramic Spacer
DEVICETitanium cage
Sponsors
BioAlpha Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
\[In Interventional Study\] * Subjects who required between L1 and S1 among those who required an extensive laminectomy or facetectomy to correct severe disc extrusion or severe spinal stenosis or those who required PLIF due to grade I or II spondylolisthesis \[In Long-term Follow-up Study\] * Subjects who are treated with bioactive glass ceramic intervertebral spacer or titanium cage in one-level PLIF surgery
Exclusion criteria
\[In Interventional Study\] * Subjects with average T-scores of L1-L4 at \<-3.0 in DEXA bone density tests * Subjects who are pregnant or breast-feeding * Subjects with a history of malignant tumor or malignant diseases (but the cases of cured disease with no relapse for the past 5 years were included in the present study) * Subjects with abnormal blood potassium and phosphorus levels * Subjects who are considered not suitable for the study by significant disease(liver disease, kidney disease, respiratory disease, metabolic disease, or psychological disease) * Subjects who are not able to comply with the study requirements * Subjects who are considered not suitable for the study by the investigator \[In Long-term Follow-up Study\] * Subjects who are not able to comply with the study requirements * Subjects who are considered not suitable for the study by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bone fusion with radiographs (X-ray) | for 36 months after surgery | Evaluation of bone fusion between bone substitutes and vertebral endplates with X-ray for 36 months(or more than 36 months) after PLIF surgery. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Bone fusion with 3-dimensional computed tomography(CT) | for 36 months after surgery | Evaluation of bone fusion between bone substitutes and vertebral endplates with 3-dimensional CT for 36 months(or more than 36 months) after PLIF surgery. |
| The Oswestry Disability Index(ODI) assessment | for 36 months after surgery | Evaluation of the Oswestry disability index questionnaire survey for 36 months(or more than 36 months) after PLIF surgery. |
| The SF(Short Form)-36 questionnaire assessment | for 36 months after surgery | Evaluation of the SF(Short Form)-36 questionnaire survey for 36 months(or more than 36 months) after PLIF surgery. |
| VAS for target site | for 36 months after surgery | Evaluation of target site pain using the visual analogue scale (VAS) for 36 months(or more than 36 months) after PLIF surgery. |
| 1.Number of Participants with Adverse Events as a Measure of Safety and Tolerability | for 36 months after surgery | Evaluation of AE |
Outcome results
None listed